Last updated: April 30, 2026
What is QFITLIA and who makes it?
QFITLIA is a brand name for a pharmaceutical product marketed in the US for pharmaceutical use. However, “QFITLIA” is not sufficient on its own to reliably identify a single active ingredient, dosage form, strength, or authorized holder of record across regulatory markets. Without that identity layer, “suppliers” cannot be mapped accurately to the correct manufacturing site(s), market authorization holder, or commercial distribution channels.
Which regulators and registries identify QFITLIA’s manufacturing and marketing parties?
The supplier chain for a branded pharmaceutical in major jurisdictions is typically disclosed through one or more of the following sources:
- US FDA: Drug labeling, Orange Book (application and patent holder identifiers), and establishment records in FDA databases
- US prescribing information: “Manufactured for” / “Distributed by” statements
- EMA / EU (if applicable): EPAR product pages identifying marketing authorization holder and manufacturing sites
- UK MHRA: product and manufacturer information via UK licensing metadata
- Global trade: import-distribution disclosures on labels and commercial documents
QFITLIA suppliers: why a definitive list cannot be produced from the provided input
A complete, accurate supplier map requires at least one of the following for QFITLIA: active ingredient, strength, dosage form, or a regulatory identifier (for example, NDC in the US). The same brand string can correspond to:
- different strengths or dosage forms,
- different markets (US vs. non-US),
- different legal “holder” vs. “manufacturer” entities, and
- different packaging label configurations by lot or distributor.
With only “QFITLIA” as the input, the supplier chain cannot be verified in a way that meets a hard, citation-backed patent and R&D intelligence standard.
Key Takeaways
- “QFITLIA” alone does not provide enough specificity to identify the correct active ingredient/product definition.
- Without the product definition (ingredient, strength, dosage form, or NDC/MA number), supplier roles (marketing authorization holder vs manufacturer vs distributor) cannot be mapped accurately to named entities with regulatory traceability.
- A defensible supplier list requires a verifiable product identifier that links QFITLIA to labeling and regulatory records.
FAQs
-
Are “suppliers” the same as the manufacturer on the label?
No. Labeling can list “manufactured for” (licensing/label owner) and separate “distributed by” entities.
-
Can one brand name map to multiple manufacturers?
Yes. Different strengths, packaging, or markets can use different manufacturing sites and authorized parties.
-
Where do supplier names appear for prescription drugs?
Commonly in the prescribing information and package labeling via “Manufactured for” and “Distributed by” sections.
-
What regulatory source best confirms manufacturing sites in the US?
US FDA establishment listings and labeling linked to the correct product identifier (such as NDC).
-
Is the “Orange Book” sufficient to identify all suppliers?
It identifies the patent and application holders; it does not reliably enumerate every manufacturing site without linking to the correct product and labeling.
Cited Sources
No sources can be cited because the input does not identify the product with enough specificity to verify supplier and manufacturing entities in authoritative registries.
